The Deciparticle ™ platform is a proprietary nanotechnology engineered to encapsulate hydrophobic molecules as uniform, sub-20 nm nanoparticles for intravenous administration. The platform improves ...

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano, a clinical-stage nanomedicine company, today announced new data ...

Lundbeck A/S (Lundbeck) today announced that new pipeline data regarding bexicaserin (LP352), a novel investigational drug for the treatment of seizures associated with Developmental and Epileptic ...

AI WAS a highlight of the 2025 European Society for Medical Oncology (ESMO) Congress, held in Berlin, Germany, with sessions ...

Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received ...

Praxis Precision Medicines, Inc. is upgraded to Strong Buy, driven by pipeline progress and positive Phase 3 data for ...

Discusses Positive Topline Results from Phase III DRAGON Trial of Tinlarebant in Stargardt Disease December 1, 2025 8:00 ...

CKM syndrome, which links heart disease, kidney disease, diabetes, and obesity, is a fairly new concept. As a result, ...

Detailed price information for Upstream Bio Inc (UPB-Q) from The Globe and Mail including charting and trades.

GUELPH, ON – November 24, 2025 – PRESSADVANTAGE – Natural Choice Medical Clinic is outlining a practical, evidence-based approach to menopause treatment for residents of Elora and surrounding ...

Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in a global Phase 3 trial for Stargardt disease, achieving a statistically significant p-value of 0.0033 Tinlarebant met ...

Good day, and thank you for joining us. Yesterday, we issued a press release relating to the Phase III HARMONi-6 data ...